Familial pulmonary alveolar proteinosis and type I interferonopathy by mutation of STAT2 (TIMS2)
Journal of Experimental Medicine · 2026
DOI: 10.1084/jem.20251331 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Conor Gruber und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA. Hauptthemen laut MEDLINE: Pulmonary Alveolar Proteinosis, STAT2 Transcription Factor, Interferon Type I, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Center for Advancement of Translational Sciences, UK Medical Research Council.
Abstract (Originalsprache)
Mutations that enhance type I interferon (IFN-I) activity cause monogenic autoinflammatory disorders termed type I interferonopathies. Along with the typical neurologic and rheumatologic manifestations, severe pulmonary disease is increasingly recognized yet poorly understood. We studied three siblings presenting with early-onset, life-threatening pulmonary alveolar proteinosis (PAP) and autoinflammatory stigmata. Genetic analysis uncovered a novel homozygous variant (R223Q) in STAT2, a key mediator of IFN-I signaling, which also facilitates feedback inhibition via USP18. R223Q STAT2 preserved signal transduction and viral control in vitro. However, cells homozygous for the R223Q variant failed to terminate IFN-I responses, owing to impaired localization of USP18. Unlike in classical forms of PAP, GM-CSF signaling remained intact. Instead, persistent IFN-I signaling antagonized monocyte migration toward chemokines essential for lung trafficking. Informed by these findings, the youngest sibling received JAK inhibitor and anti-IFN-I receptor therapy with marked clinical improvement. Collectively, type I interferonopathy by mutation of STAT2 (TIMS2) compromises monocyte chemotaxis and underlies a novel mechanism of PAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
- Columbia Center for Genetic Errors of Immunity, Vagelos College of Physicians and Surgeons, Columbia University , New York, NY, USA.
- Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Université Paris Cité, Imagine Institute, INSERM U1163, Paris, France.
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
ORCID-Profile: Conor Gruber, Meredith Ramba, Bineeta Debnath, Lorenzo Cuollo, Anna-Lena Neehus, Angelica Lee, Sofija Buta, Marta Martin-Fernandez, Jérémie Rosain, Laureline Berteloot, Philippe Drabent, Tom Le Voyer, Camille Soudée, Jessica Peel, Yoann Seeleuthner, Anne Puel, Shen-Ying Zhang, Michael J Ciancanelli, Carlos A Arango-Franco, Mélanie Migaud, Marie-Louise Frémond, Florence Renaldo, Odile Boespflug-Tanguy, Imen Dorboz, Beatrice Dubern, Nima Parvaneh, Rasol Molatefi, Mohammad Shahrooei, Darragh Duffy, Vincent Bondet, Gillian I Rice, Yanick J Crow, Thierry Jo Molina, Nathalie Boddaert, Jean-Laurent Casanova, Veronique Houdouin, Isabelle Melki, Alice Hadchouel, Jacinta Bustamante, Dusan Bogunovic
Förderung
- NIAID NIH HHS
- National Center for Advancement of Translational Sciences
- UK Medical Research Council
- National Institute of Allergy and Infectious Diseases
- French National Research Agency
- Imagine Institute
- Bettencourt-Schueller Foundation
- European Research Council
Zitieren
APA
Gruber, C., Ramba, M., Debnath, B., Cuollo, L., Neehus, A. L., Lee, A., Buta, S., Martin-Fernandez, M., Rosain, J., Berteloot, L., Drabent, P., Le Voyer, T., Soudée, C., Peel, J., Seeleuthner, Y., Puel, A., Zhang, S. Y., Ciancanelli, M. J., Arango-Franco, C. A., …, & Bogunovic, D. (2026). Familial pulmonary alveolar proteinosis and type I interferonopathy by mutation of STAT2 (TIMS2). Journal of Experimental Medicine. https://doi.org/10.1084/jem.20251331
Vancouver
Gruber C, Ramba M, Debnath B, Cuollo L, Neehus AL, Lee A, et al. Familial pulmonary alveolar proteinosis and type I interferonopathy by mutation of STAT2 (TIMS2). Journal of Experimental Medicine. 2026. doi:10.1084/jem.20251331
BibTeX
@article{Gruber2026,
author = {Gruber, Conor and Ramba, Meredith and Debnath, Bineeta and Cuollo, Lorenzo and Neehus, Anna-Lena and Lee, Angelica and Buta, Sofija and Martin-Fernandez, Marta and Rosain, Jérémie and Berteloot, Laureline and Drabent, Philippe and Le Voyer, Tom and Soudée, Camille and Peel, Jessica and Seeleuthner, Yoann and Puel, Anne and Zhang, Shen-Ying and Ciancanelli, Michael J and Arango-Franco, Carlos A and Migaud, Mélanie and Frémond, Marie-Louise and Renaldo, Florence and Boespflug-Tanguy, Odile and Dorboz, Imen and Dubern, Beatrice and Fonteneau, Tristan and Parvaneh, Nima and Molatefi, Rasol and Shahrooei, Mohammad and Duffy, Darragh and Bondet, Vincent and Rice, Gillian I and Crow, Yanick J and Molina, Thierry Jo and Boddaert, Nathalie and Casanova, Jean-Laurent and Houdouin, Veronique and Melki, Isabelle and Hadchouel, Alice and Bustamante, Jacinta and Bogunovic, Dusan},
title = {Familial pulmonary alveolar proteinosis and type I interferonopathy by mutation of STAT2 (TIMS2)},
journal = {Journal of Experimental Medicine},
year = {2026},
doi = {10.1084/jem.20251331}
}
EUVIMED